- Subject index
With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today's healthcare industry.
The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace.
The Handbook focuses on the aspects of paramount importance in the healthcare sector: Pharmacoeconomics; Pharmacogenomics; Therapeutics; Diagnostics
Areas covered include: The role of nanotechnology, genomics and cell therapy in medicine; Diagnostics; Biomarkers and technological advances; Case studies in oncology ...
Chapter 2: Changes in US Oncology Drug Reimbursement: Medicare Sets the Pace
Changes in US Oncology Drug Reimbursement: Medicare Sets the Pace
Cancer has a higher profile than almost any other disease. According to the American Cancer Society (ACS), 10.1 million US residents have been diagnosed with cancer at some time in their lives, and approximately 1.4 million US residents were expected to be diagnosed with some form of cancer in 2006. The lifetime risk of developing cancer is 1 in 2 for US men and 1 in 3 for US women. Cancer is also the second most common cause of death in the United States (after coronary heart disease), accounting for one-quarter of all deaths. The ACS forecasted that 564,830 US residents will die from cancer in ...